Trial Profile
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elevar Therapeutics
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 04 Apr 2022 Status changed from recruiting to discontinued.
- 03 Sep 2021 Planned End Date changed from 1 Dec 2020 to 31 Jan 2022.